Early and concurrent therapy of dyslipidemia and hypertension: when to start it and how to maintain patient´s good and long-term adherence?

Czech version

Authors: Vladimír Soška
Authors‘ workplace: II. interní klinika LF MU a FN U sv. Anny v Brně ; Oddělení klinické biochemie, FN u sv. Anny v Brně
Published in: Vnitř Lék 2021; 67(1): 37-40
Category:

Overview

Treatment of dyslipidemia and hypertension is a key step for reducing the risk of atherosclerotic cardiovascular disease. Dyslipidemia and hypertension often occur in one patient at the same time, so both of these risk factors need to be addressed at the same time. It is better to start therapy before the patient is at high risk of a fatal cardiovascular event. To improve the patient‘s prognosis, it is important not only to achieve the target LDL-cholesterol value and the optimal blood pressure value, but it is also very important (and often more difficult) to maintain the patient‘s good and long-term adherence to established combination pharmacotherapy. For better adherence to long-term therapy also contributes reduction the number of tablets, which can be achieved through the use of a fixed combination of statins and antihypertensive agents.

Keywords:

adherence – Antihypertensive drugs – cardiovascular diseases – cardiovascular risk – dyslipidemia – hypertension – statins

Sources

1. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur He‑ art J 2012; 33: 1635–1701.

2. WHO. Global atlas on cardiovascular disease prevention and control 2015. Available from: https://www.world‑heart‑federation.org/cvd‑roadmaps/.

3. Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012; 2012: 925046.

4. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490–1500.

5. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76: 113C–117C.

6. Ford I, Murray H, McCowan C et al. Long‑Term Safety and Efficacy of Lowering Low‑Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow‑Up of West of Scotland Coronary Prevention Study. Circulation 2016; 133: 1073–1080.

7. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower‑than‑average cholesterol concentrations, in the Anglo‑Scandinavian Cardiac Outcomes Trial – Lipid lowering arm (ASCOT‑LLA): A multicentre randomised controlled trial. Drugs 2004; 64: 43–60.

8. Gupta A, Mackay J, Whitehouse A et al. Long‑term mortality after blood pressure‑lowering and lipid‑lowering treatment in patients with hypertension in the Anglo‑Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow‑up results of a randomised factorial trial. Lancet 2018; 392: 1127–1137.

9. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low‑Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA 2019; 322: 1381–1391.

10. Ference BA, Yoo W, Alesh I et al. Effect of Long‑Term Exposure to Lower Low‑Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis. Journal of the American College of Cardiology 2012; 60: 2631–2639.

11. Ference BA, Majeed F, Penumetcha R et al. Effect of naturally random allocation to lower low‑density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomizati‑ on study. J Am Coll Cardiol 2015; 65: 1552–1561.

12. Ference BA, Julius S, Mahajan N et al. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension 2014; 63: 1182–1188.

13. Authors/Task Force M, Guidelines ESCCfP, Societies ESCNC. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205.

14. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–188.

15. Benner JS, Glynn RJ, Mogun H et al. Long‑term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–461.

16. Monane M, Bohn RL, Gurwitz JH et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population‑based study in the elderly. Am J Hypertens 1997; 10: 697–704.

17. Skoupá J. Dlouhodobá adherence ke kardiovaskulární farmakoterapii v České republice na příkladu amlodipinu a atorvastatinu. Kapitoly z kardiologie 2011; 3: 63–67.

18. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid‑lowering therapy. Arch Intern Med 2005; 165: 1147–1152.

19. Kettani FZ, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213–220.

20. Bohm M, Schumacher H, Laufs U et al. Effects of nonpersistence with medication on outcomes in high‑risk patients with cardiovascular disease. Am Heart J 2013; 166: 306–314 e307.

21. Shin S, Jang S, Lee TJ et al. Association between non‑adherence to statin and hospitalization for cardiovascular disease and all‑cause mortality in a national cohort. Int J Clin Pharmacol Ther 2014; 52: 948–956.

22. https://www.sukl.cz/modules/medication/detail.php?code=0093013 & tab=texts

23. https://www.sukl.cz/modules/medication/detail.php?kod=0148070 & tab=texts

24. https://www.sukl.cz/modules/medication/detail.php?code=0016054 & tab=texts

25. Lund TM, Torsvik H, Falch D et al. Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. Am J Cardiol 2002; 90: 784–786.

26. Hermida RC, Crespo JJ, Dominguez‑Sardina M et al. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019.

27. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high‑risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25: 484–491.